Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
47,000
Stocks News & Analysis
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.70 | 2.20 | -0.02% |
| CAC 40 | 8,249.96 | 54.75 | 0.67% |
| DAX 40 | 24,761.00 | 221.66 | 0.90% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,983.79 | 32.65 | 0.33% |
| HKSE | 26,347.24 | 8.77 | 0.03% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 51,832.80 | 1,493.32 | 2.97% |
| NZX 50 Index | 13,587.23 | 38.81 | 0.29% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,728.60 | 2.60 | 0.03% |
| SSE Composite Index | 4,023.42 | 54.58 | 1.38% |